{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-028188","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.710472+00:00","generated_at":"2026-05-26T17:04:26.887509+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inhibikase appoints Mark Iwicki as CEO; founder Milton Werner resigns","bullets":["Milton Werner resigned as CEO/board member effective Feb 13, 2025; will consult through May 13, 2025 at $44,583/month.","Mark Iwicki appointed CEO, President and director effective Feb 14, 2025; base salary $710K, bonus up to 60%, options for 15.1M shares.","Amit Munshi named independent Chair of the Board, replacing Roberto Bellini who remains a director.","Company advancing IkT-001Pro in Phase 2b trial with $110M from October financing; new CEO has PAH expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-028188","json":"https://secwatch.observer/filing/0001193125-25-028188.json","markdown":"https://secwatch.observer/filing/0001193125-25-028188.md","text":"https://secwatch.observer/filing/0001193125-25-028188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/0001193125-25-028188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/d835160d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T17:04:26.887509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a636c4fe4","claim":"Milton H. Werner resigned as Chief Executive Officer at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/0001193125-25-028188-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c8832cbd8e","claim":"Mark Iwicki was appointed as Chief Executive Officer at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Effective February 14, 2025, the Board appointed Mark Iwicki as President, Chief Executive Officer and principal executive officer of the Company (the “Appointment”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/0001193125-25-028188-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}